Document is current
Any future updates will be listed below
-
Authors
Bergersen, Kristina V.
Zheng, Ying
Rossetti, Maura
Ruffin, Felicia
Pickering, Harry
Parmar, Rajesh
Sunga, Gemalene
Chan, Liana C.
Gjertson, David
Fowler, Vance G.
Yeaman, Michael R.
Reed, Elaine F.
,
Hoffmann, Alexander
Medie, Felix
Sharma, Batu
Thaden, Joshua
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (TL1DK132768)
National Institute of Allergy and Infectious Diseases (U01AI124319)
National Institute of Allergy and Infectious Diseases (U01AI124319)
National Institute of Allergy and Infectious Diseases (U01AI124319)
- License Information
-
More Information
Article History
Received: 13 November 2024
Accepted: 7 February 2025
First Online: 18 February 2025
Declarations
:
: This study was conducted in accordance with Good Clinical Practice and Human Subjects Research as previously approved by the Duke University Medical Center (DUMC) Institutional Review Board (Approval Number: Pro00008031). The patients for this study were selected from and prospectively enrolled via an informed consent process under the Duke Institutional Review Board (IRB) Protocol # Pro00008031 between 2007 and 2017. If a patient died, written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin.
: Not applicable.
: VGF reports Grant/ Research Support: MedImmune, Cerexa/Forest/Actavis/Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Cubist/Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius; Genentech, Regeneron, BasileaPaid Consultant: Pfizer, Novartis, Galderma, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetraphase, Trius, MedImmune, Bayer, Theravance, Cubist, Basilea, Affinergy, Janssen, xBiotech, Contrafect, Regeneron, Basilea, Destiny. Membership: Merck Co-Chair V710 Vaccine. Educational fees: Green Cross, Cubist, Cerexa, Durata, Theravance; Debiopharm. Royalties: UpToDate.M.R.Y is a founder and shareholder of NovaDigm Therapeutics, Inc. which develops anti-infective vaccines and immunotherapies targeting S. aureus and other pathogens. He holds patents on anti-infectives, vaccines and immunotherapeutics targeting infectious diseases, including those caused by S. aureus.
